Joint Formulary & PAD

Sparsentan - Nephropathy

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Tablets
Associated Icons :
ICB
NICE
SPC
Restrictions / Comments :
Important

This treatment is not provided by the Trusts in Surrey Heartlands but is on formulary at other local Trusts who provide renal services. Prescribing should remain with the specialist teams.

Locally, these specialist renal centres are at Brighton, Epsom and Frimley.

Documents :
 

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Sparsentan
Indication :
Nephropathy
Group Name :
Keywords :
Primary IgA nephropathy, NICE
Brand Names Include :
Filspari
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
2

Committee Recommendations (1)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed implementation of sparsentan for treating primary IgA nephropathy in line with NICE TA 1074

Sparsentan for this indication will be considered as RED on the Joint Formulary with treatment initiation and continued prescribing by specialists in renal services

Primary care prescribers should be aware that their patient is receiving this medicine and ensure that this is recorded on the patient’s medication screen as a hospital-only drug in line with guidance on the PAD.

This will also alert the prescriber to potential side effects and interactions with other medicines prescribed in primary care. It will also ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.

Other Indications

Below are listed other indications that Sparsentan is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Nephropathy.